(ANSA) – ROME, JUNE 09 – A widely used and generic medicine used as an anti-diabetic has succeeded in an experimental phase in reducing the risks of long-term covid by 40% in more than 500 patients. The study just published in the ‘Lancet Infectious Disease journal’ is already considered a milestone, albeit with the need for further long-term analyses. But the data that emerged – according to various experts – is solid: in tests conducted at the University of Minnesota on 564 patients with non-serious and non-hospitalized covid, but at high risk for obesity and other conditions, the use of metformin for 14 days has been shown to lead to 40% fewer long covid diagnoses, compared to a group of control patients; 562 covid patients with the same characteristics had in fact received a trivial placebo. All volunteers were followed up for 10 months. Even better results were also obtained in patients who received metformin from the very first days of infection with Sars-Cov2: for them, the reduction in the risks of long covid was 63%. This is the first study by third phase – i.e. on patients – to have demonstrated that a medicine can actually reduce the risks of long covid. (HANDLE).
breaking latest news © Copyright ANSA